11th September 2014 - New research
A
retrospective analysis of randomised, double-blind, placebo-controlled clinical
trials of
entacapone
show that it improves Parkinson's Disease symptoms but often at the expense of
dyskinesia
or nausea. Entacapone is marketed as Comtan. In combination with L-dopa and
carbidopa
(the active constituents of Sinemet) Entacapone is marketed as Stalevo.
Entacapone
improved daily OFF and ON times by 0.8 hours (48
minutes)
compared with a placebo. People taking entacapone also did
better
in the standard Parkinson's Disease symptom questionnaire the
UPDRS
II, UPDRS III, and also global evaluation. Similar benefits of
entacapone
were seen in subgroups of patients with and without
dopamine
agonists or selegiline. Entacapone was generally well
tolerated.
Dyskinesia and nausea were more frequently reported by
people
taking entacapone, with 25% getting dyskinesia and 14%
getting
nausea. There was no difference in reports of hallucinations.
The
researchers suggest that results of this pooled analysis of entacapone clinical
trials
potentially
serve as a useful benchmarking data for new therapies, especially those including
L-dopa,
in people with advanced Parkinson's Disease.
For more Information go to : http://www.rxlist.com/comtan-drug.htm
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/25186800
Acta Neurologica Scandinavica [2014] Sep 3 [Epub ahead of print]
(M.Kuoppamäki, M. Vahteristo, J.Ellmén, K.Kieburtz)
No comments:
Post a Comment